Global Antibodies Market Size, Share, Trends, COVID-19 Impact & Growth Forecast Report – Segmented By Product Type (Monoclonal Antibodies, Polyclonal Antibodies and Anti-body Drug Complexes), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, CNS Disorders and Others), End User (Hospitals/Clinics, Research Institutes and Diagnostics Laboratories), Application (Medical, Experimental, Western blot, ELISA, Radioimmune Assays, Immunofluorescence and Others) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Industry Analysis (2024 to 2029)

Updated On: January, 2024
ID: 1112
Pages: 175

Global Antibodies Market Size (2024 to 2029)

As per our research report, the global antibodies market size was valued at USD 162.17 bn in 2023 and the global market is estimated to grow at a CAGR of 11.31% from 2024 to 2029 and be worth USD 343.2 billion by 2029 from USD 183.7 billion in 2024.

Antibodies are proteins produced in response to specific antigens by plasma cells. They are also called immunoglobulin. These antibodies are used for diagnostics as well as therapeutic purposes for several indications of diseases, including but not limited to rheumatoid arthritis, non-Hodgkin lymphoma, psoriasis, Crohn’s disease, macular degeneration, hypercholesterolemia, and asthma. The antibodies market is projected to witness steady growth due to several product launches. In addition, effective harmonization of product development, approval, and registration guidelines in some of the major markets, such as the United States and the European Union, can speed up the research and development of antibody-related products.

Global Antibodies Market Drivers:

The growing demand for therapeutic antibodies, including monoclonal and polyclonal antibodies is one of the key factors propelling the growth of the global antibodies market. Antibodies are also the dominant biopharmaceuticals targeting abnormal cells specifically. Therefore, many pharmaceutical and biotechnology companies have focused on developing advanced antibodies to treat chronic diseases like cancer, rheumatic heart disease, and arthritis. High drug costs, particularly biologics, are becoming increasingly important in managing healthcare costs. With increasing healthcare spending, the economic burden of cancer and other chronic diseases is growing. Improvements in the production of therapeutic antibodies have reduced the cost of manufacturing, and therefore, the penetration of antibodies has increased in cost-sensitive markets.

The patent expiry of several successful monoclonal antibodies shortly is further contributing to the growth rate of the global antibodies market. In a couple of years, most antibodies like Avastin, Herceptin, and Mabthera will lose their patents. For instance, Herceptin's license (trastuzumab) expired in July 2014 in Europe and will expire in June 2019 in the United States. Many firms, including Amgen Inc., Synthon, Biocon, and Pfizer Inc., are developing trastuzumab biosimilar, which is expected to boost demand for products producing antibodies.

Global Antibodies Market Restraints:

Variations in the antibody techniques have resulted in inadequate reproductive results. No standards for their validation reproducibility across every antibody offering. The variations in the antibodies affect the results of research and clinical screening tests. The development process of monoclonal antibodies is a time-consuming and complicated procedure. One of the main concerns is that technologies require large bioreactors and filtration systems for antibody production, which is expected to impede global antibody market growth.

Impact of COVID-19 on the global antibodies market:

In March 2020, the World Health Organization announced COVID-19 as the pandemic. The emergence of COVID-19 has positively impacted the antibody market growth during the COVID-19 period. In addition, it has boosted research activities due to the efforts made to understand the dynamics of infection. According to recent reports, most research and reagent manufacturing with personalized medicine will have a better share in the coming years. Many companies have mounted their operations to test and identify coronavirus. In addition, the latest genetic and molecular testing technologies have been used to test COVID-19.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Analysed

By Product Type, Indication, End User, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Market Leaders Profiled

Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, A.G. Scientific, Inc., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffmann-La Roche Ltd.


This research report on the global antibodies market has been segmented based on the product type, indication, end-user, application, and region.

Global Antibodies Market - By Product Type:

  • Monoclonal Antibodies
    • Murine
    • Chimeric
    • Humanized
    • Human
  • Polyclonal Antibodies
    • Type I
    • Type II
    • Type III
    • Type IV
    • Type V
    • Type VI
    • Type VII
    • Type VIII
  • Anti-body drug complexes
    • Immunogen Technology
    • Seattle Genetics Technology
    • Immunomedics Technology

Based on the product type, the monoclonal antibodies segment to dominate the global antibodies market during the forecast period. Monoclonal antibodies are laboratory-made proteins that boost the immune system to fight against harmful pathogens such as a virus. Therefore, the monoclonal market is anticipated to hold the largest market share in the coming years.

Global Antibodies Market - By Indication:

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Others)

Based on the indication, the cancer segment accounts for the leading share during the forecast period. Over the years, cancer diseases have increased due to the uncontrollable growth of abnormal cells in the body. This factor is propelling the cancer indication segment to the extent. On the other hand, the autoimmune diseases segment is anticipated to rule the market's growth rate in the coming years. 

Global Antibodies Market - By End User:

  • Hospitals/Clinics
  • Research Institute
  • Diagnostics laboratories

Based on End Users, the Cancer indication type segment is predicted to account highest market share over the forecast period due to the broad range of applications of monoclonal antibodies for the treatment of various cancers. In addition, the prevalence of cancer disease, the rising number of research activities on antibodies, and improving healthcare infrastructure facilities drive the growth of these segments.

Global Antibodies Market – By Application:

  • Medical
  • Experimental
  • Western blot
  • Radioimmune Assays
  • Immunofluorescence
  • Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

Based on Application, the medical and experimental segments are expected to have the majority share in the market as an increase in the research and development activities on antibodies' production. In addition, the rising demand for antibodies in the global market is more likely to encourage the growth of these segments.

Global Antibodies Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

North America was the market's largest revenue-generating area in the last few years. Due to the presence of many other leading biopharmaceutical and biotechnology firms in this market, this region is expected to maintain its role during the forecast period. Increasing focus on biomedical, stem cell and cancer research is the primary factor influencing the North American market growth. Like cardiovascular and blood diseases, the rising prevalence of chronic diseases is expected to drive market growth during the forecast period. American cancer society estimates that 1,735,350 people have been diagnosed with chronic diseases recently. The rising number of biotechnology and biopharmaceutical companies adopting advanced research antibodies and products to examine stem cells is more likely to accelerate the market.

The European market held a substantial share in the global antibodies market during the forecast period and is projected to register a promising CAGR during the forecast period. It is owing to the growing prevalence of cardiovascular diseases and blood diseases. Increasing demand for antibodies for research productivity and R&D expenditure and funding are expected to witness a steady rise in the coming years.

The Asia Pacific market is expected to be the fastest-growing regional market and was one of the largest market shareholding regions in 2019, with an increasing CAGR of the research antibodies and reagents market during the previous year. Moreover, improving healthcare infrastructure, lowering regulatory hurdles, and increasing pharmaceutical investments are projected to augment market growth.

The Latin American market is estimated to hike at a steady rate during the forecast period. Government investments in improving healthcare infrastructure are projected to drive market growth over the forecast period.

The Middle East Africa market had a smaller global market share but was estimated to register a healthy CAGR during the forecast period. Substantial increases in the research and development activities to develop effective diagnostic therapy and an increasing number of research activities are projected to propel the market growth of the antibodies market in this region.


Notable companies profiled in the report leading the global antibodies market are Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, A.G. Scientific, Inc., Bristol-Myers Squibb, AbbVie Inc., and F. Hoffmann-La Roche Ltd.


  • In April 2016, the U.S. approved ERELZI-Novartis biosimilar to Enbrel. The European Union subsequently approved ERELZI in April 2017. With this authorization, Novartis opened an enormous market opportunity for R.A. in 28 E.U. member states.

Please wait. . . . Your request is being processed

Frequently Asked Questions

How much is the global Antibodies Market going to be worth by 2028?

As per our research report, the global Antibodies Market size is projected to be USD 277.11 billion by 2028. 

At What CAGR, the global Antibodies Market is expected to grow from 2023 to 2028?

The global Antibodies Market is estimated to grow at a CAGR of 11.31% from 2023 to 2028. 

Which region is anticipated to witness considerable growth in the Antibodies Market?

Geographically, the APAC Antibodies Market is predicted to have the fastest growth rate in the global market from 2023 to 2028. 

Who are the leading players in the Antibodies Market?

Abbott Diagnostics, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, A.G. Scientific, Inc., Bristol-Myers Squibb, AbbVie Inc. are some of the leading players in the Antibodies Market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample